Learning from the current experience, the attempts to include a hybrid with an epitope in vaccination, optimise adjuvants with more relevance to the epitope-mediated immunity, combine with anti-HER2/neu therapies and stratify eligible patients who express low HER2/neu are the most remarkable steps for approaching the future therapeutic development for breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.